Sanofi reshapes Executive Committee to drive its next strategic phase starting September 2026

Sanofi announced changes to its Executive Committee effective September 1, 2026, aligning leadership across key business areas to support its upcoming strategic priorities. New roles include expanded responsibilities for Finance and Vaccines, with leadership shifts such as Madeleine Roach becoming President for Germany, Switzerland, and Austria. Departures include Roy Papatheodorou, Executive Vice President, General Counsel. These changes aim to enhance focus on innovation, operational efficiency, and global growth as Sanofi prepares for its next chapter.